Arcturus Therapeutics (ARCT) PT Raised to $79 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Price: $10.87 --0%
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $79.00 (from $72.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Arm Holdings (ARM) PT Lowered to $245 at JPMorgan
- Wayfair (W) PT Raised to $141 at JPMorgan
- Paycom Software (PAYC) PT Raised to $365 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
